Thermo Fisher Scientific continues to be a dominant player in the
Life Sciences market, despite regulatory headwinds. In light of
diagnostics division sale considerations and possible spending cuts, analysts have given mixed opinions about holding Thermo Fisher in your portfolio. The stock was recently downgraded by UBS based on Life Sciences R&D headwinds, though some believe the stock is oversold and a buy opportunity. Notably, Thermo Fisher has scored a
$94.5 million U.S. Government contract to provide the Navy with advanced radiation detection systems. The FDA has approved Thermo Fisher's
Oncomine Dx Express Test and
NGS Assay, bolstering their position in the diagnostics space. However, some investors worry about current shareholders' returns given the present stock prices. Recovery looks imminent and Thermo Fisher has some considerable strategies, including a $4 billion Diagnostics Sale and mRNA collaboration expansion, a $2 Billion U.S. investment plan, a sustainable centrifuge line launch, and considerations about selling parts of its diagnostics unit. Thermo Fisher's financial prospects look decent, despite recent stock market underperformance. They will continue to invest in U.S. innovation and support clients' manufacturing needs.
Thermo Fisher Scientific TMO News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Fri, 11 Jul 2025 23:22:14 GMT -
Rating 2
- Innovation -5
- Information 8
- Rumor 0
